Compare POR & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | POR | ALKS |
|---|---|---|
| Founded | 1889 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.7B |
| IPO Year | N/A | 1991 |
| Metric | POR | ALKS |
|---|---|---|
| Price | $53.98 | $33.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $47.00 | $42.85 |
| AVG Volume (30 Days) | 949.1K | ★ 2.1M |
| Earning Date | 02-20-2026 | 02-25-2026 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | N/A | ★ 2.44 |
| EPS | ★ 2.78 | 2.02 |
| Revenue | ★ $3,511,000,000.00 | $1,521,338,000.00 |
| Revenue This Year | $4.51 | N/A |
| Revenue Next Year | $5.12 | $23.22 |
| P/E Ratio | $18.92 | ★ $16.50 |
| Revenue Growth | ★ 5.09 | 1.08 |
| 52 Week Low | $39.55 | $25.17 |
| 52 Week High | $52.67 | $36.45 |
| Indicator | POR | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 74.83 | 54.54 |
| Support Level | $50.13 | $33.04 |
| Resistance Level | $51.65 | $35.34 |
| Average True Range (ATR) | 0.88 | 1.03 |
| MACD | 0.21 | -0.21 |
| Stochastic Oscillator | 100.00 | 40.18 |
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation along with 300 megawatts of energy storage.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.